Literature DB >> 2785414

T cells from eosinophilic patients produce interleukin-5 with interleukin-2 stimulation.

H Enokihara1, S Furusawa, H Nakakubo, H Kajitani, S Nagashima, K Saito, H Shishido, Y Hitoshi, K Takatsu, T Noma.   

Abstract

Anti-murine (m) interleukin-5 (IL-5) antibody was found to inhibit eosinophil (Eo) colony formation stimulated by recombinant human (rh) IL-5, but did not inhibit the production of Eo stimulated by rh IL-3 or granulocyte-macrophage colony-stimulating factor (GM-CSF). Conditioned medium (CM) prepared from eosinophilic patients' T cells with interleukin-2 (IL-2) stimulation (T-IL-2-CM), was found to contain CFU-Eo growth-stimulating factor. Using anti-mIL-5 antibody, we demonstrated that T-IL-2-CM from patients with eosinophilia contained a significant amount of IL-5. We also detected IL-5 mRNA in T cells from eosinophilic patients with IL-2 stimulation. These results suggest that IL-5 plays an important role in the induction of selective eosinophilia in humans and that IL-5 is produced from T cells with IL-2 stimulation.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2785414

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  22 in total

Review 1.  Cytokines in asthma.

Authors:  K F Chung; P J Barnes
Journal:  Thorax       Date:  1999-09       Impact factor: 9.139

Review 2.  Synergy of Interleukin (IL)-5 and IL-18 in eosinophil mediated pathogenesis of allergic diseases.

Authors:  Hemanth Kumar Kandikattu; Sathisha Upparahalli Venkateshaiah; Anil Mishra
Journal:  Cytokine Growth Factor Rev       Date:  2019-05-10       Impact factor: 7.638

3.  Interleukin-5 in growth and differentiation of blood eosinophil progenitors in asthma: effect of glucocorticoids.

Authors:  H P Kuo; C H Wang; H C Lin; K S Hwang; S L Liu; K F Chung
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

4.  Engineering of a functional interleukin-5 monomer: a paradigm for redesigning helical bundle cytokines with therapeutic potential in allergy and asthma.

Authors:  R R Dickason; J D English; D P Huston
Journal:  J Mol Med (Berl)       Date:  1996-09       Impact factor: 4.599

Review 5.  Eosinophils in the 1990s: new perspectives on their role in health and disease.

Authors:  A J Wardlaw
Journal:  Postgrad Med J       Date:  1994-08       Impact factor: 2.401

6.  IL-5 in post-traumatic eosinophilic pleural effusion.

Authors:  L Schandené; B Namias; A Crusiaux; M Lybin; R Devos; T Velu; P Capel; R Bellens; M Goldman
Journal:  Clin Exp Immunol       Date:  1993-07       Impact factor: 4.330

7.  Human eosinophils express functional interleukin 2 receptors.

Authors:  T H Rand; D S Silberstein; H Kornfeld; P F Weller
Journal:  J Clin Invest       Date:  1991-09       Impact factor: 14.808

8.  Expression of interleukin-5 and granulocyte-macrophage colony-stimulating factor in human peripheral blood mononuclear cells after activation with phorbol myristate acetate.

Authors:  D Z Staynov; T H Lee
Journal:  Immunology       Date:  1992-01       Impact factor: 7.397

9.  Eosinophilic colitis in a patient with acute myeloid leukemia after allogeneic bone marrow transplantation.

Authors:  Takashi Ashida; Takahiro Shimada; Kazunobu Kawanishi; Junichi Miyatake; Akihisa Kanamaru
Journal:  Int J Hematol       Date:  2003-07       Impact factor: 2.490

10.  Eosinophil hematopoietins antagonize the programmed cell death of eosinophils. Cytokine and glucocorticoid effects on eosinophils maintained by endothelial cell-conditioned medium.

Authors:  E Her; J Frazer; K F Austen; W F Owen
Journal:  J Clin Invest       Date:  1991-12       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.